Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2

Laryngoscope

Volumn 111, Issue 8, 2001, Pages 1472-1478

  Son, Young Ik ^a,b   Mailliard, Robbie B ^a   Watkins, Simon C ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Apoptosis; Dendritic cells; Immunotherapy; Interleukin 2; Squamous cell carcinoma

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN CELL; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET B RADIATION;

EID: 0034903325     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200108000-00026     Document Type: Article

References (26)

1. Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma: An immunohistochemical study
2. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
3. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
4. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
5. Dendritic cells acquire antigen from apoptotic cells and induce Class I-restricted CTLs
6. Dendritic cell/macrophage precursors capture exogenous antigen for MHC Class I presentation by dendritic cells
7. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
8. Response of resting human peripheral blood natural killer cells to interleukin 2
9. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity, and histologic findings
10. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
11. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity
12. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
13. Defining apoptosis
14. Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B
15. Phototherapy
16. Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers
17. Use of nonyl acridine orange and rhodamine 123 to follow biosynthesis and functional assembly of mitochondrial membrane during L1210 cell cycle
18. Dendritic cells and the control of immunity
19. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
20. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
21. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
22. Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
23. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2
24. The future of interleukin-2: Enhancing therapeutic anticancer vaccines
25. Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells
26. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity